Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2017 10/12/2017 10/13/2017 10/16/2017 10/17/2017 Date
452.97(c) 447.15(c) 442.96(c) 445.68(c) 445.01 Last
1 197 831 704 789 718 075 508 714 325 513 Volume
-1.77% -1.28% -0.94% +0.61% -0.15% Change
More quotes
Financials ($)
Sales 2017 5 747 M
EBIT 2017 2 409 M
Net income 2017 1 338 M
Finance 2017 2 281 M
Yield 2017 -
Sales 2018 6 240 M
EBIT 2018 2 674 M
Net income 2018 1 480 M
Finance 2018 4 019 M
Yield 2018 -
P/E ratio 2017 38,72
P/E ratio 2018 35,16
EV / Sales2017 7,91x
EV / Sales2018 7,01x
Capitalization 47 756 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in inventing medicines for people with serious diseases.It includes Arcalyst, Dupixent, Eylea, Kevzara, and Praluent injections.The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M.... 
Sector
Biotechnology & Medical Research
Calendar
11/08 | 12:30pmEarnings Release
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
06:58p Regeneron-Sanofi drug succeeds mid-stage study
04:36p IBD Announces First Annual Biotech Innovator Awards
10:18a REGENERON PHARMACEUTICALS : to Report Third Quarter 2017 Financial and Operating..
10/16 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Phase 2 Study Results f..
10/13 SANOFI : - Internationally Acclaimed Writer and Executive Producer of HBO's The ..
10/12 REGENERON PHARMACEUTICALS : Announces New Collaborations with HHS to Develop Ant..
10/12 REGENERON PHARMACEUTICALS : 3 Key Industry Updates Showcased Next Month
10/11 REGENERON PHARMACEUTICALS : to Report Third Quarter 2017 Financial and Operating..
10/10 SANOFI : Regeneron Pharmaceuticals, Inc. - Appellate Court Orders a New Trial an..
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
More news
Sector news : Bio Therapeutic Drugs
06:39pDJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
06:48aDJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on REGENERON PHARMACEUTICALS 
REGENERON PHARMACEUTICALS - 09/19
A long term support level to be taken advantage of
BUY
REGENERON PHARMACEUTICALS - 08/21
One can take advantage of the trading range to enter new positions
BUY
More Strategies
Latest Tweets
04:57pHere Are the Best Looking Revenue Charts (part 3 of 4) - Dr. Fly $REGN $ALXN ..
1
03:45a$REGN - Canaccord Genuity Reaffirms "Buy" Rating for Regeneron Pharmaceutical.. 
03:21aRegeneron Pharmaceuticals's buy rating reiterated at Canaccord Genuity.  
12:50aAnalysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and.. 
10/16Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients .. 
More tweets
Qtime:706
News from SeekingAlpha
10/16 Aimmune teams up with Regeneron and Sanofi on AR101 and Dupixent in patients ..
10/16 Regeneron and Sanofi's Dupixent shows treatment effect in mid-stage eosinophi..
10/11 ANAPTYSBIO ATOPIC DERMATITIS DATA IM : Buy The Secondary
10/10 An In-Depth Look At Alexion's Competition And Upcoming Catalysts
10/09 Regeneron Stock Shows Promise Despite High Valuation Multiple
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 498 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Charles A. Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS20.67%47 756
GILEAD SCIENCES11.65%104 409
VERTEX PHARMACEUTICALS107.56%39 003
ACTELION23.24%29 757
GENMAB22.08%13 881
EXELIXIS, INC.66.06%8 529